Please wait while the formulary information is being retrieved.
CAVERJECT (ALPROSTADIL)
- Erectile dysfunction
- Edex Intracavernosal Kit
- Caverject Intracavernosal Syringe
- Caverject Intracavernosal Solution
- Caverject Impulse Intracavernosal Kit
- By Indication
10 mcg intracavernosal kit
- Inject 10 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse
20 mcg intracavernosal kit
- Inject 20 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse
40 mcg intracavernosal kit
- Inject 40 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse
10 mcg intracavernosal syringe
- Inject 10 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse
20 mcg intracavernosal syringe
- Inject 20 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse
20 mcg intracavernosal solution
- Inject 1 milliliter (20 mcg) by intra-cavernosal route once 10-30 minutes before intended intercourse
40 mcg intracavernosal solution
- Inject 1 milliliter (40 mcg) by intra-cavernosal route once 10-30 minutes before intended intercourse
Impulse 10 mcg intracavernosal kit
- Inject 10 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse
Impulse 20 mcg intracavernosal kit
- Inject 20 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse
Erectile dysfunction
- Inject 5 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse
- Inject 10 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse
- Inject 7.5 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse
- Inject 20 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse
- Inject 2.5 mcg by intra-cavernosal route once 10-30 minutes before intended intercourse
- Inject 0.125 milliliter (5 mcg) by intra-cavernosal route once 10-30 minutes before intended intercourse
- Inject 0.25 milliliter (5 mcg) by intra-cavernosal route once 10-30 minutes before intended intercourse
- Inject 0.25 milliliter (10 mcg) by intra-cavernosal route once 10-30 minutes before intended intercourse
- Inject 0.5 milliliter (10 mcg) by intra-cavernosal route once 10-30 minutes before intended intercourse
- Inject 0.75 milliliter (15 mcg) by intra-cavernosal route once 10-30 minutes before intended intercourse
- Inject 0.375 milliliter (15 mcg) by intra-cavernosal route once 10-30Minutes before intended intercourse
- Inject 0.5 milliliter (20 mcg) by intra-cavernosal route once 10-30 minutes before intended intercourse
- Inject 1 milliliter (20 mcg) by intra-cavernosal route once 10-30 minutes before intended intercourse
- Inject 0.625 milliliter (25 mcg) by intra-cavernosal route once 10-30Minutes before intended intercourse
- Inject 0.75 milliliter (30 mcg) by intra-cavernosal route once 10-30 minutes before intended intercourse
- Inject 1 milliliter (40 mcg) by intra-cavernosal route once 10-30 minutes before intended intercourse
- Inject 0.125 milliliter (2.5 mcg) by intra-cavernosal route once 10-30 minutes before intended intercourse
- None
Contraindicated
- None
Severe
Moderate
- None
- Deformity of erection of the penis
- Fibrosis of corpus cavernosum
- Leukemia
- Lymphoid leukemia
- Multiple myeloma
- Penile angulation
- Penile prosthesis
- Peyronie's disease
- Sickle cell disease
- Sickle cell trait
Contraindicated
- Increased risk of bleeding due to coagulation disorder
Severe
Moderate
- None
CAVERJECT (ALPROSTADIL)
- Erectile dysfunction
- None
- Injection site sequelae
- Pain
- Painful erection
More Frequent
Severe
Less Severe
- Priapism
- Back pain
- Dizziness
- Ecchymosis
- Edema of penis
- Flu-like symptoms
- Headache disorder
- Hemorrhage
- Hyperhidrosis
- Hypertension
- Penile angulation
- Penile hematoma
- Prostatitis
- Sinusitis
- Skin rash
- Upper respiratory infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Fibrosis of corpus cavernosum
- Hypotension
- Male genital tract infection
- Peyronie's disease
- Supraventricular premature beats
- Testicular swelling
Less Severe
- Hematospermia
- Increased urinary frequency
- Pruritus of skin
- Testicular pain
- Vasodilation of blood vessels
Contraindicated
None
Severe Precaution
Alprostadil (Intracavernosal)
Intracavernous route not indicated in pediatrics. No safety and efficacy data available.
- 1 Day – 18 Years
- Intracavernous route not indicated in pediatrics. No safety and efficacy data available.
Management or Monitoring Precaution
None
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Erectile dysfunction | |
F52.21 | Male erectile disorder |
N52 | Male erectile dysfunction |
N52.0 | Vasculogenic erectile dysfunction |
N52.01 | Erectile dysfunction due to arterial insufficiency |
N52.02 | Corporo-venous occlusive erectile dysfunction |
N52.03 | Combined arterial insufficiency and corporo-venous occlusive erectile dysfunction |
N52.1 | Erectile dysfunction due to diseases classified elsewhere |
N52.2 | Drug-induced erectile dysfunction |
N52.3 | Postprocedural erectile dysfunction |
N52.31 | Erectile dysfunction following radical prostatectomy |
N52.32 | Erectile dysfunction following radical cystectomy |
N52.33 | Erectile dysfunction following urethral surgery |
N52.34 | Erectile dysfunction following simple prostatectomy |
N52.35 | Erectile dysfunction following radiation therapy |
N52.36 | Erectile dysfunction following interstitial seed therapy |
N52.37 | Erectile dysfunction following prostate ablative therapy |
N52.39 | Other and unspecified postprocedural erectile dysfunction |
N52.8 | Other male erectile dysfunction |
N52.9 | Male erectile dysfunction, unspecified |
0-9 | A-Z |
---|---|
F52.21 | Male erectile disorder |
N52 | Male erectile dysfunction |
N52.0 | Vasculogenic erectile dysfunction |
N52.01 | Erectile dysfunction due to arterial insufficiency |
N52.02 | Corporo-venous occlusive erectile dysfunction |
N52.03 | Combined arterial insufficiency and corporo-venous occlusive erectile dysfunction |
N52.1 | Erectile dysfunction due to diseases classified elsewhere |
N52.2 | Drug-induced erectile dysfunction |
N52.3 | Postprocedural erectile dysfunction |
N52.31 | Erectile dysfunction following radical prostatectomy |
N52.32 | Erectile dysfunction following radical cystectomy |
N52.33 | Erectile dysfunction following urethral surgery |
N52.34 | Erectile dysfunction following simple prostatectomy |
N52.35 | Erectile dysfunction following radiation therapy |
N52.36 | Erectile dysfunction following interstitial seed therapy |
N52.37 | Erectile dysfunction following prostate ablative therapy |
N52.39 | Other and unspecified postprocedural erectile dysfunction |
N52.8 | Other male erectile dysfunction |
N52.9 | Male erectile dysfunction, unspecified |
Formulary Reference Tool